Prescribed safer opioid supply: A scoping review of the evidence
| dc.contributor.author | Ledlie, Shaleesa | |
| dc.contributor.author | Garg, Ria | |
| dc.contributor.author | Cheng, Clare | |
| dc.contributor.author | Kolla, Gillian | |
| dc.contributor.author | Antoniou, Tony | |
| dc.contributor.author | Bouck, Zachary | |
| dc.contributor.author | Gomes, Tara | |
| dc.date.accessioned | 2024-03-28T15:15:05Z | |
| dc.date.available | 2024-03-28T15:15:05Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Background: Safer opioid supply programs provide prescription pharmaceutical opioids, often with supportive services, to people at high risk of experiencing harms related to substance use. However, questions regarding the effectiveness and safety of this practice remain. We conducted a scoping review of literature describing client outcomes from formal opioid supply programs providing prescriptions for pharmaceutical opioids, and the perceptions of involved clients/providers. Methods: We performed a scoping review of peer-reviewed studies and grey literature published between January 1, 2012, to September 12, 2023. We included articles reporting either safer opioid supply client outcomes or clients/providers perspectives. Extracted data included study objectives, substance use patterns, client outcomes, client/provider perspectives, and estimates of effectiveness and/or harm. Results: Our search yielded 1,597 articles. Following removal of duplicates and application of exclusion criteria, 24 publications comprising 17 peer-reviewed and seven grey literature publications were included in our study. We generated eight themes summarizing topics in the available literature: opioid-related toxicities, infectious complications, other clinical outcomes, client-reported outcomes, program access barriers, diversion, program retention, and costs to the healthcare system. Specific findings included low rates of opioid toxicities, improved physical and mental health, and improved quality of life among clients. A lack of access to adequate opioid doses and the limited range of opioid options offered within safer opioid supply programs was described by clients and providers as a potential reason for diversion and a barrier to program access. Conclusions: Generally, evidence suggests that safer opioid supply programs are beneficial to clients through measurable outcomes. However, the available literature has important limitations, including limited inferences about the effectiveness, safety, and potential for diversion within safer opioid supply programs. Further research is needed to support the ongoing evaluation of safer opioid supply programs as one component of a multifactorial response to escalating rates of substance-related harms. | |
| dc.description.reviewstatus | Reviewed | |
| dc.description.scholarlevel | Faculty | |
| dc.description.sponsorship | This work was supported by grants from the Canadian Institutes of Health Research (Grants #153070 and #178163). S. Ledlie is supported by an Ontario Graduate Scholarship and the Network for Improving Health Systems Trainee Award. R. Garg is supported by a Canadian Institutes of Health Research Canada Graduate Scholarship – Doctoral Research Award. G. Kolla is supported by a Banting postdoctoral fellowship from the Canadian Institutes of Health Research. T. Gomes is supported by a Tier 2 Canada Research Chair. | |
| dc.identifier.citation | Ledlie, S., Garg, R., Cheng, C., Kolla, G., Antoniou, T., Bouck, Z., & Gomes, T. (2024). Prescribed safer opioid supply: A scoping review of the evidence. International Journal of Drug Policy, 125, 104339. https://doi.org/10.1016/j.drugpo.2024.104339 | |
| dc.identifier.uri | https://doi.org/10.1016/j.drugpo.2024.104339 | |
| dc.identifier.uri | https://hdl.handle.net/1828/16323 | |
| dc.language.iso | en | |
| dc.publisher | International Journal of Drug Policy | |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | en |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.title | Prescribed safer opioid supply: A scoping review of the evidence | |
| dc.type | Article |